Back to School: How biopharma can reboot drug development. Access exclusive analysis here

AGI Therapeutics, Williamsburg Holdings LLC deal

AGI received an exclusive, 12-month option to license Williamsburg's IP

Read the full 103 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE